Highest-materiality recent filing
Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027
Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances
Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cartesian Therapeutics board member Murat Kalayoglu resigns effective March 31, 2026
Director Murat Kalayoglu, M.D., Ph.D. resigned from board effective March 31, 2026 to pursue other opportunities.
Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027
Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated
Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise
Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis
100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track
Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
Cartesian Therapeutics Chair Carrie Cox resigns; CEO Carsten Brunn named Chairman, bylaw amended
Carrie Cox resigned from the Board and as Chair on Oct. 29, 2025, to focus on other commitments; not related to any disagreement.
Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025
CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.
Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025
Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.
Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.
First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.
Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track
Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.
CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.
Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track
Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track
Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
Cartesian Therapeutics files 8-K with corporate slide deck; no material news evident
Slide deck titled 'Pioneering mRNA Cell Therapy for Autoimmunity' dated March 2025 furnished as Exhibit 99.1.
On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.
Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025
Max materiality 0.85 · Median 0.60 · Most common event leadership